Search

Your search keyword '"Siddiqui, Emad"' showing total 289 results
Start Over Author "Siddiqui, Emad"
289 results on '"Siddiqui, Emad"'

10. Fezolinetant impact on health‐related quality of life for vasomotor symptoms due to the menopause: Pooled data from SKYLIGHT 1 and SKYLIGHT 2 randomised controlled trials.

Author

Cano, Antonio, Nappi, Rossella E., Santoro, Nanette, Stute, Petra, Blogg, Martin, English, Marci L., Morga, Antonia, Scrine, Ludmila, Siddiqui, Emad, and Ottery, Faith D.

Subjects
QUALITY of life, HOT flashes, LABOR productivity, ANALYSIS of covariance, SYMPTOMS
Abstract

Objective: To assess the effect of fezolinetant treatment on health‐related quality of life using pooled data from SKYLIGHT 1 and 2 studies. Design: Prespecified pooled analysis. Setting: USA, Canada, Europe; 2019–2021. Population: 1022 women aged ≥40 to ≤65 years with moderate‐to‐severe vasomotor symptoms (VMS; minimum average seven hot flushes/day), seeking treatment for VMS. Methods: Women were randomised to 12‐week double‐blind treatment with once‐daily placebo or fezolinetant 30 or 45 mg. Completers entered a 40‐week, active extension (those receiving fezolinetant continued that dose; those receiving placebo re‐randomised to fezolinetant received 30 or 45 mg). Main outcome measures: Mean changes from baseline to weeks 4 and 12 on Menopause‐Specific Quality of Life (MENQoL) total and domain scores, Work Productivity and Activity Impairment questionnaire specific to VMS (WPAI‐VMS) domain scores, Patient Global Impression of Change in VMS (PGI‐C VMS); percentages achieving PGI‐C VMS of 'much better' (PGI‐C VMS responders). Mean reduction was estimated using mixed model repeated measures analysis of covariance. Results: Fezolinetant 45 mg mean reduction over placebo in MENQoL total score was −0.57 (95% confidence interval [CI] −0.75 to −0.39) at week 4 and −0.47 (95% CI −0.66 to −0.28) at week 12. Reductions were similar for 30 mg. MENQoL domain scores were also reduced and WPAI‐VMS scores improved. Twice as many women receiving fezolinetant reported VMS were 'much better' than placebo based on PGI‐C VMS assessment. Conclusions: Fezolinetant treatment was associated with improvement in overall QoL, measured by MENQoL, and work productivity, measured by WPAI‐VMS. A high proportion receiving fezolinetant felt VMS were 'much better' based on PGI‐C VMS responder analysis. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. The role of serotonin (5HT) and 5HT antagonists in urological cancers

Author

Siddiqui, Emad Jawed

Subjects
616.994607
Abstract

Neuroendocrine (NE) differentiation takes place in both prostate and bladder cancer tissue. These NE cells release growth factors including neuropeptides and biogenic amines which correlate with tumour progression, differentiation, androgen independence, angiogenesis and poor prognosis. Serotonin (5-hydroxytryptamine 5HT), a monoamine neurotransmitter, plays a role in regulation of growth, gene expression and may function as a proto- oncogene. 5HT acts as a growth factor in tumours such as small cell carcinoma of the lung and colonic carcinoma. The in vitro effect of 5HT and 5HT antagonists on prostate and bladder cancer cell growth was evaluated. Cell culture and proliferation assay studies established a significant increase in growth proliferation by 5HT. Furthermore, there was a significant growth inhibition by 5HTiA and 5HTiB antagonists on prostate cancer (PC3) cells and bladder cancer (HT1376) cells. FACS analysis in PC3 cells demonstrated cell cycle arrest and apoptosis when treated with 5HTia and 5HTib antagonists. Immuno-staining for 5HT- A and 5HT-ib receptors was seen in PC3 cells, HT1376 cells, as well as in human prostate and bladder cancer tissue. Western blot analysis demonstrated 5HT-IA and 5HT1B receptor proteins in both prostate and bladder cancer cells and tissue. Ethical approval was obtained and the Helsinki Declaration of Human Rights was strictly adhered to throughout this study. These results imply that a 5HT system exists in both prostate and bladder cancer tissue. 5HTia, and in particular 5HT1B receptor antagonists, warrant further investigation as potential anti-neoplastic agents. A growth inhibitory effect of an alpha adrenoceptor antagonist (doxazosin) on PC3 and HT1376 cells was also demonstrated. This growth inhibition is independent of the antagonist action on alphai-adrenoceptors. Incubation of PC3 cells with 5HT or 5HTib agonist partially reversed the growth inhibitory effect of doxazosin. Doxazosin may modulate the action of 5HT, possibly at the receptor level. Doxazosin (or more effective analogues) commonly used in the treatment of benign prostatic hyperplasia, may be potential chemotherapeutic agents.

Published
2007

26. Corrigendum to 'Evaluation of the impact, treatment patterns, and patient and physician perceptions of vasomotor symptoms associated with menopause in Europe and the United States' [Maturitas 164 (October 2022) 38-45]

Author

Stute, Petra, Cano, Antonio, Thurston, Rebecca C, Small, Mark, Lee, Lauren, Scott, Megan, Siddiqui, Emad, and Schultz, Neil M

Subjects
Obstetrics and Gynecology, 610 Medicine & health, 610 Medizin und Gesundheit, General Biochemistry, Genetics and Molecular Biology
Published
2022
Full Text
View/download PDF

32. Additional file 1 of Qualitative study: burden of menopause-associated vasomotor symptoms (VMS) and validation of PROMIS Sleep Disturbance and Sleep-Related Impairment measures for assessment of VMS impact on sleep

Author

English, Marci, Stoykova, Boyka, Slota, Christina, Doward, Lynda, Siddiqui, Emad, Crawford, Rebecca, and DiBenedetti, Dana

Abstract

Additional file 1: Online Resource 1. Description of Semi-Structured Interview Guide. Online Resource 2. Additional Representative Quotations

Published
2021
Full Text
View/download PDF

37. Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo

Author

Chapple, C.R., Cruz, Francisco, Cardozo, L., Staskin, David, Herschorn, Sender, Choudhury, Nurul, Heesakkers, J.P., Siddiqui, Emad, Chapple, C.R., Cruz, Francisco, Cardozo, L., Staskin, David, Herschorn, Sender, Choudhury, Nurul, Heesakkers, J.P., and Siddiqui, Emad

Abstract

Contains fulltext : 214085.pdf (Publisher’s version ) (Open Access)

Published
2020

43. Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo

Author

Chapple, Christopher R., primary, Cruz, Francisco, additional, Cardozo, Linda, additional, Staskin, David, additional, Herschorn, Sender, additional, Choudhury, Nurul, additional, Stoelzel, Matthias, additional, Heesakkers, John, additional, and Siddiqui, Emad, additional

Published
2020
Full Text
View/download PDF

48. A critical appraisal of the principal guidelines for neurogenic lower urinary tract dysfunction using the AGREE II instrument6

Author

Jaggi, Ashley, Drake, Marcus, Siddiqui, Emad, Nazir, Jameel, Giagos, Vasileios, and Fatoye, Francis

Subjects
clinical guidelines, Centre for Surgical Research, neurogenic lower urinary tract dysfunction, health care economics and organizations
Abstract

AIMS: The process of identifying research questions, synthesising and interpreting evidence, and weight given to health economics differs between the clinical guidelines (CGs) for neurogenic lower urinary tract dysfunction (NLUTD). Consequently, the quality also varies which can have implications for clinical practice. METHODS: We used the Appraisal of Guidelines for Research and Evaluation (AGREE) instrument to assess the quality of the National Institute for Health and Care Excellent (NICE), European Association of Urology (EAU) and the International Consultations on Incontinence (ICI) CGs on neurogenic bladder. RESULTS: The NICE CGs were deemed to be of the highest quality (overall score of 92%). NICE were the only guidelines to systematically incorporate cost-effectiveness research into their recommendations. The EAU CGs received an overall score of 83% and the ICI CGs achieved the lowest overall score (75%). The highest scoring domain amongst all the CGs was scope purpose (86%) and the lowest scoring domain was applicability (69%). All guidelines were recommended for use (mostly with some modifications). CONCLUSIONS: All CGs had their inherent advantages and disadvantages, though all were still deemed to be of high quality. Incorporating cost-effectiveness research would be near impossible for guidelines with a broad-country remit. Incorporating the AGREE II instrument in the development of CGs and better collaboration between the ICI, NICE and EAU could improve the quality, and consistency between NLUTD CGs and ultimately improve health outcomes for this important patient group.

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results